Dr Reddy's Laboratories Ltd. has launched Atocor-R (Atorvastatin + Ramipril) in India. It is the first such combination to be approved by DCGI and has completed a multi-centre clinical trial data on Indian patients.
It is a one of its kind combination that has two blockbuster molecules, atorvastatin and ramipril combined together for the first time as a fixed dose combination.
Atocor-R is used in the treatment of patients with both essential hypertension and hypercholesterolemia. It is available in two fixed dose combinations of Atocor-R 2.5 (atorvastatin 10mg + ramipril 2.5 mg) and Atocor-R 5 (atorvastatin 10mg + ramipril 5 mg) and comes is packs of 10.
According to ORG IMS March 2008, Atorvastatin market is currently valued at Rs 300 crore growing at over 34 per cent annually and Ramipril market is about Rs 145 crore growing at over 15 per cent annually.
(source:www.pharmabiz.com)
No comments:
Post a Comment